InvestSMART

Zelira Therapeutics Limited (ASX:ZLD)

ALERT: Price-sensitive ASX Announcement for ZLD
Current share price for ZLD : $0.500 0.15 (42.86%)+
Announcement
Release
27 Oct 2025 2:33PM
Price at Release
$0.350
Full Release
download
Summary
Zelira Therapeutics Limited continues to advance its clinical development and commercialization efforts, particularly with the HOPE® 1 SPV program targeting Phelan McDermid Syndrome with autism. The company finalized its IND submission, setting the stage for Phase 1 trials. Financially, Zelira secured a non-dilutive R&D loan facility and received additional funding through unsecured loan notes from directors, maintaining a cash position of $172k at the end of Q1 FY2026. Operational expenses for this quarter amounted to a net cash outflow of $711k, which included costs related to research and development, marketing, and staff. Zelira remains committed to its growth strategy through clinical validation and expanding market presence globally.
Key Points
  • Zelira Therapeutics progressed its HOPE® 1 SPV clinical development program.
  • Finalized Investigational New Drug (IND) submission for HOPE® 1 targeting Phelan McDermid Syndrome with ASD.
  • Zelira implemented a non-dilutive R&D loan facility secured against expected R&D Tax incentive rebate.
  • Received unsecured loan notes of USD$150,000 from directors for working capital.
  • Net cash outflow from operations for Q1 FY2026 was $711k.
  • Focused on clinical validation and product development, particularly through FDA clinical trials.
  • Zelira is generating revenue from its proprietary medications and has expanded commercialisation efforts into new markets.
  • Zelira's cash position at the end of the quarter was $172k.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.